

Medicine	Indication	Further Information	Type	LSCMMG planned
Acarizax 12 SQ-HDM oral lyophilisate	Treatment of house dust mite sensitisation according to SPC definitions, see: https://www.medicines.org.uk/emc/product/12905	Requested by ENT consultant, ELHT	Major	? NICE expected 12 Feb 2025. Draft guidance does not recommend.
ITULAZAX 12 SQ-Bet sublingual lyophilisate	Treatment of moderate-to-severe allergic rhinitis induced by pollen from the birch homologous group	Requested by Consultant ENT Lancashire Teaching Hospitals NHS Foundation Trust	Major	Uncertain – similar product to Acarizax
Nefopam	For treatment of pain	Pharmacy, BHTTr	Major	February 2025
Cytisine	Smoking cessation and reduction of nicotine cravings in smokers who are willing to stop smoking	Requested by Medicines Management Pennine locality and Public Health Specialist Lancashire County Council	Major	February 2025
Dapoxetine	Treatment of premature ejaculation	Requested by sexual health specialist service	Major	February 2025
Diclofenac oral	Initiation of treatment by Rheumatologists	Currently Green (restricted) for short term treatment of post-op pain, renal colic and lithotripsy only	Moderate	March 2025
Semaglutide	For cardiovascular risk reduction	Raised by Fylde ICB locality, discussed at FWG – suggested reviewed	Major	March 2025
Drospirenone	Contraception	Raised at NW Medicines Management collaborative meeting. Product included in national PGD	Major	April 2025
Bismuth potassium with metronidazole and tetracycline hydrochloride	In combination with omeprazole, for the eradication of Helicobacter pylori and prevention of relapse of peptic ulcers in patients with active or a history of H. pylori associated ulcers.	Supported by SMC, prioritised at December 2024 LSCMMG	Moderate	April 2025